Metastatic Ewing's sarcoma: Remission induction and survival

F. A. Hayes, E. I. Thompson, L. Parvey, B. Rao, L. Kun, D. Parham, H. O. Hustu

Research output: Contribution to journalArticle

52 Scopus citations

Abstract

Eighteen patients with previously untreated metastatic Ewing's sarcoma (ES) entered a protocol designed to evaluate the response rate to cyclophosphamide and doxorubicin induction therapy delivered before delayed surgery and delayed lower dose, limited-field radiation therapy, (RT), and maintenance chemotherapy. With chemotherapy and delayed surgery, 14 of 18 were rendered free of gross tumor. RT was delivered to the primary site of 11 of these responding patients, plus four of those not free of gross disease. Following RT, two more attained complete clinical remission. Site of primary or metastases did not influence outcome; however, the size of the primary at diagnosis did appear to do so. Ten patients remain disease-free 16 to 82 months (median, 47 months) from diagnosis.

Original languageEnglish (US)
Pages (from-to)1199-1204
Number of pages6
JournalJournal of Clinical Oncology
Volume5
Issue number8
DOIs
StatePublished - Jan 1 1987

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Metastatic Ewing's sarcoma: Remission induction and survival'. Together they form a unique fingerprint.

  • Cite this

    Hayes, F. A., Thompson, E. I., Parvey, L., Rao, B., Kun, L., Parham, D., & Hustu, H. O. (1987). Metastatic Ewing's sarcoma: Remission induction and survival. Journal of Clinical Oncology, 5(8), 1199-1204. https://doi.org/10.1200/JCO.1987.5.8.1199